Healthcare: Sector Looks Undervalued with Pullback After US Election and Obesity Data
Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...
Tracking the ‘quad-demic’
Cook your food thoroughly (especially seafood and shellfish) to at least 145 degrees Fahrenheit. Clean and sanitize surfaces ...
Moderna target nearly halved by Morgan Stanley on weak guidance
Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.
Moderna's Road To Stopping The Red
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Moderna price target lowered to $38 from $70 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...
Moderna’s Financial Outlook: Hold Rating Amidst Competitive Challenges and Strategic Adjustments
In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Kashmir Life23h
Human Metapneumovirus (HMPV): A Looming Global Threat or a False Alarm?
Kashmir's leading scientist and gastroenterologist, Prof M Sultran Khuroo writes about the evolution of the Human ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.